J&J re­leas­es the first big da­ta cut in the RSV vac­cine race, set­ting bar for Glax­o­SmithK­line and Pfiz­er

The world’s largest vac­cine com­pa­nies — and some am­bi­tious biotechs — have been rac­ing for years now to de­vel­op an in­oc­u­la­tion for RSV, one of the dead­liest sea­son­al virus­es of the pre-Covid era. Da­ta on any of the ex­per­i­men­tal jabs, though, have been slow com­ing.

On Sun­day, how­ev­er, J&J an­nounced in a large mid-stage tri­al that its RSV vac­cine was 80% ef­fec­tive at pre­vent­ing in­fec­tions that re­quired med­ical at­ten­tion in adults over 65. It was 70% ef­fec­tive against pre­vent­ing any type of symp­to­matic in­fec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.